[Coronary vasodilatation induced by acetylcholine in the isolated hearts of guinea pig and mice: differential contributions of nitric oxide and postacyclin]. 2008

V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki

We have studied the involvement of nitric oxide (NO) and prostacyclin (PGI2) as well as muscarinic m2 and m3 receptors in the coronary vasodilatation induced by acetylcholine in the isolated hearts of guinea pig and mouse perfused according to the Langendorff method. In the guinea pig heart, a coronary vasodilator response to acetylcholine was profoundly decreased by the NO-synthase inhibitor L-N(G)-nitroarginine methyl ester (L-NAME, 10(-4) M), while in the mouse heart this response was blocked by the cyclooxygenase inhibitor indomethacin (5 x 10(-6) M). In both cases, the muscarinic m3 receptor antagonist 4-diphenylacetoxy-N-methylpiperidine (4-DAMP, 3 x 10(-8) M) blocked the acetylcholine-induced vasodilator response, while the muscarinic m2 antagonist methoctramine (3 x 10(-7) M) had no effect. It was concluded that the vasodilator effect of acetylcholine depends on NO in the coronary circulation of guinea pig and on PGI2 in the coronary circulation of mouse. In both cases, the coronary vasodilation induced by acetylcholine is mediated by muscarinic m3 receptors.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D010880 Piperidines A family of hexahydropyridines.
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D003331 Coronary Vessels The veins and arteries of the HEART. Coronary Arteries,Sinus Node Artery,Coronary Veins,Arteries, Coronary,Arteries, Sinus Node,Artery, Coronary,Artery, Sinus Node,Coronary Artery,Coronary Vein,Coronary Vessel,Sinus Node Arteries,Vein, Coronary,Veins, Coronary,Vessel, Coronary,Vessels, Coronary
D003959 Diamines Organic chemicals which have two amino groups in an aliphatic chain. Diamine
D005260 Female Females

Related Publications

V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
March 1993, The American journal of physiology,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
August 1996, European journal of clinical investigation,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
September 2003, Inflammation research : official journal of the European Histamine Research Society ... [et al.],
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
January 1998, Life sciences,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
October 2006, Journal of the Society for Gynecologic Investigation,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
June 1995, The American journal of physiology,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
November 1997, Endocrinology,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
January 1997, International archives of allergy and immunology,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
June 1998, Cardiovascular research,
V I Kozlovskiĭ, and P Gwozdz, and L Drelicharz, and V V Zinchuk, and S Chlopicki
January 1992, British journal of pharmacology,
Copied contents to your clipboard!